Nothing Special   »   [go: up one dir, main page]

RU2499592C2 - Фармацевтическая композиция для лечения ушных заболеваний - Google Patents

Фармацевтическая композиция для лечения ушных заболеваний Download PDF

Info

Publication number
RU2499592C2
RU2499592C2 RU2010147298/15A RU2010147298A RU2499592C2 RU 2499592 C2 RU2499592 C2 RU 2499592C2 RU 2010147298/15 A RU2010147298/15 A RU 2010147298/15A RU 2010147298 A RU2010147298 A RU 2010147298A RU 2499592 C2 RU2499592 C2 RU 2499592C2
Authority
RU
Russia
Prior art keywords
composition according
active substance
modulator
composition
antagonist
Prior art date
Application number
RU2010147298/15A
Other languages
English (en)
Other versions
RU2010147298A (ru
Inventor
Джей ЛИХТЕР
Бенедикт ФОЛЛЬРАТ
Эндрю М. ТРЭММЕЛ
Сергио Г. ДЮРОН
Фабрис ПЬЮ
Луис А. ДЕЛЛАМЭРИ
Цян Е
Карл ЛЕБЕЛ
Майкл Кристофер СКАЙФ
Джеффри П. ХАРРИС
Original Assignee
Отономи, Инк.
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Отономи, Инк., Дзе Регентс Оф Дзе Юниверсити Оф Калифорния filed Critical Отономи, Инк.
Publication of RU2010147298A publication Critical patent/RU2010147298A/ru
Application granted granted Critical
Publication of RU2499592C2 publication Critical patent/RU2499592C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к области медицины. Композиция для лечения заболевания уха вводится в барабанную полость, включает сополимер полиоксиэтилена и полиоксипропилена, активное вещество, выбранное из иммуномодулятора, антагониста вазопрессина, модулятора ионных каналов, антагониста рецептора нейрокинина, ингибитора обратного захвата серотонина, модулятора рецептора НМДА, аналога простагландина, препарата, действующего на центральную нервную систему, модулятора рецептора ГАМК, цитотоксического средства, антиоксиданта, модулятора глутаматного рецептора или ингибитора кальциневрина. Изобретение обеспечивает замедленное высвобождение активного вещества во внутреннее ухо в течение периода времени, как минимум, 7 суток. 13 з.п. ф-лы, 3 ил., 114 пр.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165
Figure 00000166
Figure 00000167
Figure 00000168
Figure 00000169
Figure 00000170
Figure 00000171
Figure 00000172
Figure 00000173
Figure 00000174
Figure 00000175
Figure 00000176
Figure 00000177
Figure 00000178
Figure 00000179
Figure 00000180
Figure 00000181
Figure 00000182
Figure 00000183
Figure 00000184
Figure 00000185
Figure 00000186
Figure 00000187
Figure 00000188
Figure 00000189
Figure 00000190
Figure 00000191
Figure 00000192
Figure 00000193
Figure 00000194
Figure 00000195
Figure 00000196
Figure 00000197
Figure 00000198
Figure 00000199
Figure 00000200
Figure 00000201
Figure 00000202
Figure 00000203
Figure 00000204
Figure 00000205
Figure 00000206
Figure 00000207
Figure 00000208
Figure 00000209
Figure 00000210
Figure 00000211
Figure 00000212
Figure 00000213
Figure 00000214
Figure 00000215
Figure 00000216
Figure 00000217
Figure 00000218
Figure 00000219
Figure 00000220
Figure 00000221
Figure 00000222
Figure 00000223
Figure 00000224
Figure 00000225
Figure 00000226
Figure 00000227
Figure 00000228
Figure 00000229
Figure 00000230
Figure 00000231
Figure 00000232
Figure 00000233
Figure 00000234
Figure 00000235
Figure 00000236
Figure 00000237
Figure 00000238
Figure 00000239
Figure 00000240
Figure 00000241
Figure 00000242
Figure 00000243

Claims (14)

1. Композиция для введения в барабанную полость, предназначенная для лечения заболевания уха, включающая:
сополимер полиоксиэтилена и полиоксипропилена;
активное вещество, выбранное из иммуномодулятора, антагониста вазопрессина, модулятора ионных каналов, антагониста рецептора нейрокинина, ингибитора обратного захвата серотонина, модулятора рецептора НМДА, аналога простагландина, препарата, действующего на центральную нервную систему, модулятора рецептора ГАМК, цитотоксического средства, антиоксиданта, модулятора глутаматного рецептора или ингибитора кальциневрина;
причем композиция обеспечивает замедленное высвобождение активного вещества во внутреннее ухо в течение периода времени, как минимум, 7 суток.
2. Композиция по п.1, в которой активным веществом является препарат, действующий на центральную нервную систему.
3. Композиция по п.2, в которой препарат, действующий на центральную нервную систему, представляет собой диазепин.
4. Композиция по п.1, в которой активным веществом является модулятор ионных каналов.
5. Композиция по п.4, в которой модулятор ионных каналов представляет собой ретигабин.
6. Композиция по п.1, в которой активным веществом является модулятор глутаматного рецептора.
7. Композиция по п.1, которая представляет собой приемлемый для ушей термообратимый гель.
8. Композиция по п.1, в которой сополимер полиоксиэтилена и полиоксипропилена представляет собой полоксамер 407.
9. Композиция по п.1, которая представляет собой жидкость, пригодную для введения с помощью шприца с тонкой иглой или канюли.
10. Композиция по любому из пп.1-9, дополнительно содержащая усилитель проникновения.
11. Композиция по любому из пп.1-9, в которой активное вещество находится в форме свободного основания, соли, пролекарства, или их комбинации.
12. Композиция по любому из пп.1-9, в которой активное вещество состоит из отдельных частиц.
13. Композиция по п.12, в которой активное вещество находится, по существу, в форме микронизированных частиц.
14. Композиция по п.1, где заболевание или состояние уха представляет собой болезнь Меньера, внезапную нейросенсорную тугоухость, вызванную шумом, потерю слуха, возрастную потерю слуха, аутоиммунное заболевание уха, вертиго или тиннитус.
RU2010147298/15A 2008-04-21 2009-04-21 Фармацевтическая композиция для лечения ушных заболеваний RU2499592C2 (ru)

Applications Claiming Priority (43)

Application Number Priority Date Filing Date Title
US4654308P 2008-04-21 2008-04-21
US61/046,543 2008-04-21
US4887808P 2008-04-29 2008-04-29
US61/048,878 2008-04-29
US12771308P 2008-05-14 2008-05-14
US61/127,713 2008-05-14
US5562508P 2008-05-23 2008-05-23
US61/055,625 2008-05-23
US6042508P 2008-06-10 2008-06-10
US61/060,425 2008-06-10
US7371608P 2008-06-18 2008-06-18
US61/073,716 2008-06-18
US7458308P 2008-06-20 2008-06-20
US61/074,583 2008-06-20
US7657608P 2008-06-27 2008-06-27
US7656708P 2008-06-27 2008-06-27
US61/076,567 2008-06-27
US61/076,576 2008-06-27
US8245008P 2008-07-21 2008-07-21
US61/082,450 2008-07-21
US8383008P 2008-07-25 2008-07-25
US8387108P 2008-07-25 2008-07-25
US61/083,871 2008-07-25
US61/083,830 2008-07-25
US8609408P 2008-08-04 2008-08-04
US8610508P 2008-08-04 2008-08-04
US61/086,105 2008-08-04
US61/086,094 2008-08-04
US8790508P 2008-08-11 2008-08-11
US8795108P 2008-08-11 2008-08-11
US61/087,951 2008-08-11
US61/087,905 2008-08-11
US8827508P 2008-08-12 2008-08-12
US61/088,275 2008-08-12
US9438408P 2008-09-04 2008-09-04
US61/094,384 2008-09-04
US10111208P 2008-09-29 2008-09-29
US61/101,112 2008-09-29
US14003308P 2008-12-22 2008-12-22
US61/140,033 2008-12-22
US16023309P 2009-03-13 2009-03-13
US61/160,233 2009-03-13
PCT/US2009/041320 WO2009132050A2 (en) 2008-04-21 2009-04-21 Auris formulations for treating otic diseases and conditions

Publications (2)

Publication Number Publication Date
RU2010147298A RU2010147298A (ru) 2012-05-27
RU2499592C2 true RU2499592C2 (ru) 2013-11-27

Family

ID=41217397

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010147298/15A RU2499592C2 (ru) 2008-04-21 2009-04-21 Фармацевтическая композиция для лечения ушных заболеваний

Country Status (13)

Country Link
US (8) US9132087B2 (ru)
EP (1) EP2278999A4 (ru)
JP (6) JP2011518195A (ru)
KR (6) KR20190026056A (ru)
CN (2) CN102014957B (ru)
AU (1) AU2009239429B2 (ru)
BR (1) BRPI0910850B1 (ru)
CA (1) CA2721927C (ru)
HK (1) HK1209055A1 (ru)
IL (2) IL208549A (ru)
MX (1) MX2010011545A (ru)
RU (1) RU2499592C2 (ru)
WO (1) WO2009132050A2 (ru)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2551359C1 (ru) * 2013-11-28 2015-05-20 Олег Ростиславович Михайлов Наноразмерная слабо закристаллизованная модификация 4-метил-n-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2751697C1 (ru) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Средство для лечения отитов наружного слухового прохода у собак

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
KR20190026056A (ko) 2008-04-21 2019-03-12 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
BRPI0912482A2 (pt) 2008-05-14 2020-08-18 Otonomy, Inc composições de corticosteróide de liberação controlada e métodos para o tratamento de distúrbios auriculares
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
GB2461962B (en) * 2008-07-25 2011-02-16 Otonomy Inc Slow release NMDA receptor antagonist for otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CA2733918A1 (en) * 2008-08-11 2010-02-18 Auckland Uniservices Limited The treatment of hearing loss
AU2009307825A1 (en) 2008-10-22 2010-04-29 Rick FRIEDMAN Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
US8987328B2 (en) * 2008-10-30 2015-03-24 Trinity Laboratories, Inc. Esters of capsaicinoids as dietary supplements
US10143711B2 (en) 2008-11-24 2018-12-04 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
EP2299976A4 (en) * 2008-12-22 2014-07-23 Otonomy Inc SELF-CONTROLLED RELEASE SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR TREATING OTIC DISORDERS
NZ596780A (en) 2009-06-05 2013-04-26 13Therapeutics Inc Immunoregulatory peptides and methods of use
EP2470015B1 (en) 2009-08-24 2016-01-13 Hough Ear Institute Nitrone compounds for treating sensorineural hearing loss
EP2470019A4 (en) * 2009-08-25 2013-03-13 Cardiokine Biopharma Llc COMPOSITIONS FOR THE ADMINISTRATION OF NON-SOLUBLE AGENTS
US20140076336A1 (en) * 2009-09-17 2014-03-20 Ascentia Health, Inc. Ear insert for relief of tmj discomfort and headaches
EP2490722A4 (en) * 2009-10-21 2014-03-05 Otonomy Inc MODULATION OF THE TEMPERATURE OF GELIFICATION OF FORMULATIONS CONTAINING POLOXAMERS
CN102008470B (zh) * 2010-05-24 2012-08-29 中国人民解放军第二军医大学 复方制剂及其预防和治疗噪声性听力损伤的用途
HK1161509A2 (en) * 2010-06-04 2012-07-27 Comprehensive Drug Entpr Ltd Oral meclizine aqueous formulations with taste flavoring agent
WO2011156631A2 (en) * 2010-06-09 2011-12-15 Joule Unlimited Technologies, Inc. Methods and compositions to extract carbon-based products from host cells
DE102010030053A1 (de) * 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
KR20130087379A (ko) * 2010-06-18 2013-08-06 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노-알킬시클로헥산 유도체의 국소 사용을 위한 겔 제형
KR101134622B1 (ko) * 2010-08-12 2012-04-09 한국원자력연구원 암포테리신 ｂ의 서방성 수화겔 및 이의 제조방법
CA2811202A1 (en) 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off-flavor masking agent
US20130045957A1 (en) * 2011-02-18 2013-02-21 Otonomy, Inc. Prevention of and Recovery from Drug-Induced Ototoxicity
EP2678004A1 (en) 2011-02-25 2014-01-01 Eydo Pharma Nanocapsulation of essential oils for preventing or curing infectious diseases alone or with an antibiotic
US8580748B2 (en) * 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
CN102805896A (zh) * 2011-05-30 2012-12-05 惠觅宙 经皮给药方法、制剂和系统
WO2012168710A1 (en) * 2011-06-07 2012-12-13 Autifony Therapeutics Limited Hydantoin derivates as kv3 inhibitors
JP6170047B2 (ja) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポトーシス−ターゲティングナノ粒子
RU2480214C1 (ru) 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
US20140341940A1 (en) * 2011-11-09 2014-11-20 Iseu da Silva Nunes Immunomodulator for the treatment of cancerous tumors in the epithelial tissue lining surfaces inside or outside body organs
EP2790729A4 (en) * 2011-12-12 2015-08-12 Orbis Biosciences Inc PARTICULATE FORMULATIONS WITH DELAYED RELEASE
US9034347B2 (en) * 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
WO2013123298A1 (en) 2012-02-17 2013-08-22 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
EP2817009A1 (en) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
EP2819741B1 (en) 2012-02-27 2018-03-28 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
US20130288981A1 (en) * 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
US9861651B2 (en) * 2012-07-16 2018-01-09 Cornell University Use of nicotinamide riboside to treat hearing loss
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
JP6579956B2 (ja) 2012-11-28 2019-09-25 アフィオス コーポレーション 神経変性疾患および他の疾患の治療のための併用治療薬および方法
EP3702443B1 (en) 2013-03-14 2022-01-19 The Brigham and Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion and culture
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
CN110420316A (zh) * 2013-06-18 2019-11-08 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
EA201690323A1 (ru) 2013-08-27 2016-07-29 Отономи, Инк. Способы лечения заболеваний уха у детей
EP2853533A1 (de) * 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
KR101653630B1 (ko) * 2014-02-20 2016-09-02 아주대학교산학협력단 시스테인 류코트리엔 수용체 길항제 및 은행잎 추출물을 포함하는 감각신경성 난청의 치료 또는 예방용 약학 조성물
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
JP2017513870A (ja) * 2014-04-23 2017-06-01 オーリス メディカル エージーＡｕｒｉｓ Ｍｅｄｉｃａｌ Ａｇ 耳鳴りの治療と予防のための方法及び組成物
US10010585B2 (en) * 2014-06-16 2018-07-03 Massachusetts Eye And Ear Infirmary Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
IL299964A (en) * 2014-09-03 2023-03-01 Massachusetts Inst Technology Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
KR20170057451A (ko) * 2014-10-01 2017-05-24 에이엘에스 마운틴 엘엘씨 비이온성 계면 활성제와 함께 아스피린, 메트포르민 및 세로토닌을 포함하는 약학 조성물
WO2016130489A1 (en) * 2015-02-09 2016-08-18 Slingshot Biosciences, Inc. Hydrogel particles with tunable optical properties and methods for using the same
MX2017010638A (es) 2015-02-20 2018-05-07 Univ Oregon Health & Science Derivados de sobetiroma.
KR101636733B1 (ko) * 2015-02-24 2016-07-07 인제대학교 산학협력단 에키노크롬 a를 유효성분으로 함유하는 운동능력 증진용 건강식품 및 이를 이용한 운동능력 증진방법
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
BR112018001900A2 (pt) * 2015-07-28 2018-09-18 Otonomy, Inc. composições agonistas de trkb ou trkc e métodos para o tratamento de condições óticas
WO2017075136A1 (en) * 2015-10-27 2017-05-04 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
EP3373907A4 (en) * 2015-11-11 2019-12-18 Qrono, Inc. EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
EP3943090A1 (en) 2016-01-29 2022-01-26 Massachusetts Eye & Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
US10772563B2 (en) * 2016-02-26 2020-09-15 Med-El Elektromedizinische Geraete Gmbh Detection of electrically evoked stapedius reflex
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
KR101785455B1 (ko) 2016-03-16 2017-11-20 전남대학교산학협력단 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물
BR112018071560A2 (pt) 2016-04-21 2019-02-12 Astrocyte Pharmaceuticals, Inc. compostos e métodos para tratar condições neurológicas e cardiovasculares
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
US20190254997A1 (en) * 2016-07-21 2019-08-22 The Regents Of The University Of California Methods for inducing stereocilia on hair cells
WO2018053173A1 (en) 2016-09-16 2018-03-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
WO2018081614A1 (en) * 2016-10-31 2018-05-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
US11253193B2 (en) * 2016-11-08 2022-02-22 Cochlear Limited Utilization of vocal acoustic biomarkers for assistive listening device utilization
US20190321493A1 (en) * 2016-11-18 2019-10-24 Mayo Foundation For Medical Education And Research Materials and methods for treating regional pain
WO2018111908A1 (en) * 2016-12-13 2018-06-21 The Regents Of The University Of California Xenobiotic-free culture system to expand human limbal stem cells
RU2630129C1 (ru) * 2016-12-19 2017-09-05 Государственное бюджетное учреждение здравоохранения города Москвы "Научно-исследовательский клинический институт оториноларингологии им. Л.И. Свержевского" Департамента здравоохранения города Москвы Способ определения степени эндолимфатического гидропса при болезни меньера, выбор тактики лечения и оценка ее эффективности
WO2018125746A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
JP2020506930A (ja) * 2017-02-02 2020-03-05 オトラーヌム アーゲー ベタヒスチンを含む鼻腔内組成物
EP3612152A4 (en) * 2017-04-19 2021-02-17 Phio Pharmaceuticals Corp. TOPICAL ADMINISTRATION OF NUCLEIC ACID COMPOUNDS
JP6443783B2 (ja) 2017-06-07 2018-12-26 株式会社エコ・プランナー 熱交換装置の制御方法及び熱交換装置並びに水冷式ヒートポンプ冷暖房装置
US12076415B2 (en) * 2017-08-18 2024-09-03 King Fahd University Of Petroleum And Minerals Use of nano-sized clay crystallites to restore adhesion among tumor and aging stem cells
CN111432807A (zh) 2017-10-06 2020-07-17 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
US11484515B2 (en) * 2017-12-12 2022-11-01 University of Pittsburgh—of the Commonwealth System of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
WO2019126783A1 (en) * 2017-12-22 2019-06-27 Otonomy, Inc. Triglyceride otic formulations and uses thereof
AU2019207704B2 (en) * 2018-01-09 2024-05-02 Dompé Farmaceutici S.P.A. Growth factor otic formulations
US20210361820A1 (en) * 2018-01-31 2021-11-25 Systagenix Wound Management, Limited Antimicrobial composition, dressing, dressing components, and method
WO2019157370A1 (en) 2018-02-09 2019-08-15 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
JP7311855B2 (ja) 2018-02-09 2023-07-20 アストロサイト ファーマシューティカルズ， インコーポレイテッド 嗜癖および関連する障害を処置するための化合物および方法
WO2019163012A1 (ja) * 2018-02-21 2019-08-29 国立大学法人信州大学 液体塞栓剤組成物
US20190307885A1 (en) * 2018-04-04 2019-10-10 Alivio Therapeutics, Inc. Self-assembled gels for controlled delivery of biologics and methods of making thereof
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2019346585A1 (en) 2018-09-26 2021-04-29 Astrocyte Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
US11827596B2 (en) 2018-12-12 2023-11-28 Autobahn Therapeutics, Inc. Thyromimetics
JP2022513212A (ja) * 2018-12-12 2022-02-07 キュアレーター， インコーポレイテッド 聴覚バイオマーカーを検出するためのシステム及び方法
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
WO2020180624A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
EP3962533A4 (en) * 2019-04-30 2023-01-25 The Medical College of Wisconsin, Inc. PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF
CN110101871B (zh) * 2019-05-30 2022-03-25 广东工业大学 一种包埋白藜芦醇的制备方法
EP3977092A1 (en) * 2019-05-30 2022-04-06 Beckman Coulter, Inc. Methods and systems for immobilizing a biological specimen for microscopic imaging
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020254249A1 (en) * 2019-06-21 2020-12-24 Proqr Therapeutics Ii B.V. Delivery of nucleic acids for the treatment of auditory disorders
NO20211406A1 (en) * 2019-09-24 2021-11-19 Halliburton Energy Services Inc Fragile and normal viscoelastic components of drilling fluid gels
CN115279354B (zh) * 2020-01-13 2024-07-19 正群生物科技有限公司 氯胺酮用于治疗恶病质的用途
US20230122991A1 (en) * 2020-01-24 2023-04-20 Otonomy, Inc. Growth factor formulation for condition associated with otic event
EP3854385A1 (en) 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
BR112022015925A2 (pt) 2020-03-11 2022-10-04 Iterum Therapeutics International Ltd Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos
EP4149431A4 (en) * 2020-05-13 2024-05-29 Spiral Therapeutics Inc. GEL-FORMING SOLUTIONS FOR THE ADMINISTRATION OF COMPOUNDS INTO THE INNER EAR
RU2741252C1 (ru) * 2020-06-01 2021-01-22 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ выбора метода хирургического лечения пациентов с болезнью меньера
KR20240127867A (ko) * 2020-08-10 2024-08-23 지로파, 인코포레이티드 국소 전달을 위한 조성물 및 방법
US20240245602A1 (en) * 2020-08-28 2024-07-25 President And Fellows Of Harvard College Drug combination kits and methods of drug delivery
CN112618571B (zh) * 2020-09-30 2023-04-07 杭州贤石生物科技有限公司 治疗骨科疾病的可注射水凝胶微球及其制备方法与应用
CN112125969A (zh) * 2020-09-30 2020-12-25 东南大学 生物因子rimbp2在维持内耳毛细胞特性上的应用
US20240016766A1 (en) 2020-11-26 2024-01-18 Alain Moussy Pharmaceutical composition for treatment of inner ear disorders through local administration in the tympanic area
CN112557158B (zh) * 2021-02-28 2021-05-28 中国工程物理研究院核物理与化学研究所 一种用于空气样品中氙的分离纯化收集装置
CN113425852B (zh) * 2021-05-24 2022-06-03 北京大学 一种可穿过血迷路屏障的偶联物及其制备方法
CN113456580B (zh) * 2021-07-21 2024-03-22 沈阳化工大学 一种白藜芦醇原位凝胶制备及其表征方法
KR102675908B1 (ko) 2021-09-03 2024-06-14 충남대학교산학협력단 내이 질환 치료를 위한 국소 약물전달용 나노입자 함유 하이드로겔 조성물 및 이의 제조방법
KR20240116721A (ko) 2021-10-29 2024-07-30 슬링샷 바이오사이언시즈 인코포레이티드 피더 세포 및 합성 항원 제시 세포로서의 하이드로겔 입자
IL313499A (en) * 2021-12-23 2024-08-01 Cilcare Dev Derivatives of 4-phenyl-tetrahydropyridine for the treatment of hearing diseases
WO2023154770A1 (en) * 2022-02-09 2023-08-17 9 Meters Biopharma, Inc. Compositions and methods for inhibiting rho kinase
WO2023230430A1 (en) * 2022-05-21 2023-11-30 Neuvision Development Llc Topical ocular administration of ambroxol for ocular pain
WO2023235885A1 (en) 2022-06-02 2023-12-07 Slingshot Biosciences, Inc. Apoptotic cell mimic
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus
EP4316462A1 (en) * 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of bdnf for the treatment of sensorineural hearing loss
CN115317446A (zh) * 2022-09-01 2022-11-11 黑龙江迪龙制药有限公司 一种含有天麻素的复方制剂及其制备方法
WO2024148287A2 (en) * 2023-01-06 2024-07-11 Gateway Biotechnology, Inc. Combination therapies for treatment of hearing disorders
CN116019818B (zh) * 2023-01-18 2024-03-19 上海交通大学医学院附属第九人民医院 一种用于预防、改善和/或治疗耳蜗突触损伤的组合物及其应用
CN117448350B (zh) * 2023-10-18 2024-05-10 哈尔滨学院 一种利用桑黄Pb-bHLH9基因提高酿酒酵母多重胁迫抗性的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107791B1 (en) * 1998-09-04 2007-05-30 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4474572A (en) 1981-09-29 1984-10-02 Syntex (U.S.A.) Inc. Implanting device and implant magazine
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4758435A (en) 1986-08-11 1988-07-19 American Cyanamid Company Estradiol implant composition and method for preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
EP0504257A4 (en) 1989-11-29 1993-03-03 Brigham And Women's Hospital (ala il-8) 77 as a leukocyte adhesion inhibitor
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
IT1251151B (it) 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
EP0551626A1 (en) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6083354A (en) 1992-07-24 2000-07-04 Matsushita Electric Industrial Co., Ltd. Treatment method for diamonds
ATE258685T1 (de) 1993-03-09 2004-02-15 Baxter Int Makromolekulare mikropartikel und verfahren zur ihrer herstellung
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO1995004533A2 (en) * 1993-08-04 1995-02-16 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
PT754032E (pt) 1994-04-08 2002-05-31 Atrix Lab Inc Composicoes liquidas para difusao
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
EP0766564A4 (en) 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
GB9505032D0 (en) 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6201065B1 (en) * 1995-07-28 2001-03-13 Focal, Inc. Multiblock biodegradable hydrogels for drug delivery and tissue treatment
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
FR2742750B1 (fr) 1995-12-22 1998-01-30 Oreal Nouveaux derives de l'acide l-2-oxothiazolidine 4-carboxylique et leur utilisation pour le soin de la peau
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
WO1997031008A1 (en) 1996-02-23 1997-08-28 Industrial Research Limited Enzyme detection/assay method and substrates
AU2676397A (en) 1996-04-18 1997-11-07 University Technology Corporation Methods for treating middle and inner ear disorders
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US20020052390A1 (en) 1997-10-22 2002-05-02 Jens Ponikau Methods and materials for treating and preventing inflammation of mucosal tissue
DE19748763A1 (de) 1997-11-05 1999-05-06 Hans Peter Zenner Verwendung von Vasopressin-Antagonisten
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
WO2000007603A2 (en) 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US8197461B1 (en) 1998-12-04 2012-06-12 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
JP3572570B2 (ja) 1999-02-01 2004-10-06 オーテックス株式会社 カチオン重合性有機物質用の重合開始剤
DK1165564T3 (da) 1999-04-08 2009-06-08 Ind Res Ltd Fremgangsmåde til fremstilling af inhibitorer af nukleosidmetabolisme
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
PT1180159E (pt) 1999-05-28 2008-12-05 Targeted Genetics Corp Métodos e composições para abaixamento do nível de factor de necrose tumoral (tnf) nos distúrbios associados a tnf
SK286857B6 (sk) 1999-06-23 2009-06-05 Sanofi-Aventis Deutschland Gmbh Substituované benzimidazoly, spôsob ich prípravy, ich použitie a liečivo, ktoré ich obsahuje
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
US6548527B2 (en) * 2000-03-27 2003-04-15 The General Hospital Corporation Treatments for immune-mediated ear disorders
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US7289110B2 (en) * 2000-07-17 2007-10-30 Human Messaging Ab Method and arrangement for identifying and processing commands in digital images, where the user marks the command, for example by encircling it
UA81743C2 (ru) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ЧЕЛОВЕКА, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С ФАКТОРОМ НЕКРОЗА ОПУХОЛЕЙ АЛЬФА (ФНПα), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ РЕВМАТОИДНОГО АРТРИТА
US7109331B2 (en) 2000-08-29 2006-09-19 Industrial Research Limited 5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
WO2002030353A2 (en) 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
JP2004532797A (ja) 2000-10-12 2004-10-28 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
IL155519A0 (en) 2000-10-26 2003-11-23 Tularik Inc Antiinflammation agents
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
WO2002059084A2 (en) 2001-01-04 2002-08-01 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
JP2004529088A (ja) 2001-02-01 2004-09-24 ブリストル−マイヤーズ　スクイブ　カンパニー ＩｋＢキナーゼ（ＩＫＫ）のインヒビターを用いる炎症性および免疫疾患の処置法
US20060269602A1 (en) 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
WO2002094265A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
TWI324925B (en) 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
JP2005506983A (ja) 2001-09-19 2005-03-10 ファルマシア・コーポレーション 炎症の治療のための置換ピラゾリル化合物
JP2005510466A (ja) 2001-09-19 2005-04-21 ファルマシア・コーポレイション 炎症の治療のための置換されたピラゾロ化合物
ATE414697T1 (de) 2001-10-04 2008-12-15 Smithkline Beecham Corp Nf-kb-inhibitoren
EP1453848A4 (en) 2001-11-21 2009-09-09 Einstein Coll Med PRODUCTS AND ACTIVITIES OF SIR2
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
MXPA04005427A (es) 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
JP2005526714A (ja) 2002-01-17 2005-09-08 ニューロジェン・コーポレーション カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体
US20030229333A1 (en) 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
JP2003277383A (ja) 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
PL375552A1 (en) 2002-05-22 2005-11-28 Amgen Inc. Vanilloid receptor ligands and their medical applications
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7144888B2 (en) 2002-08-08 2006-12-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7589110B2 (en) 2002-09-06 2009-09-15 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
WO2004039328A2 (en) 2002-10-29 2004-05-13 Oregon Health & Science University Fludrocortisone treatment for hearing loss
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US8802116B2 (en) * 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
AU2003900887A0 (en) * 2003-02-27 2003-03-13 Novasel Australia Pty Ltd Poloxamer emulsion preparations
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
WO2004094401A1 (en) 2003-04-21 2004-11-04 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
DE50304744D1 (de) * 2003-04-28 2006-10-05 Biofrontera Bioscience Gmbh Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
US20040247575A1 (en) 2003-06-03 2004-12-09 Caplice Noel M. Smooth muscle progenitor cells
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
NZ545506A (en) 2003-07-24 2009-11-27 Euro Celtique Sa Therapeutic agents useful for treating pain
AU2004278382B2 (en) 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7700086B2 (en) 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
US20050137122A1 (en) 2003-12-17 2005-06-23 Alcon, Inc. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
JP2005220070A (ja) 2004-02-05 2005-08-18 Medgel Corp 神経再生および保護のための生体吸収性高分子ハイドロゲル製剤
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
KR20070011483A (ko) 2004-05-12 2007-01-24 아벤티스 파마슈티칼스 인크. Ｉｋｂ 키나제 억제제로서의 실질적으로 순수한2-｛[2-(2-메틸아미노-피리미딘-4-일)-1ｈ-인돌-5-카르보닐]-아미노｝-3-(페닐피리딘-2-일-아미노)-프로피온산
WO2005115527A2 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060046970A1 (en) 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US8498681B2 (en) 2004-10-05 2013-07-30 Tomophase Corporation Cross-sectional mapping of spectral absorbance features
BRPI0517549A (pt) 2004-10-05 2008-10-14 Merz Pharma Gmbh & Co Kgaa novas propenonas cìclicas e acìclicas para o tratamento de distúrbios do snc
US20060105967A1 (en) 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Flavone derivatives as TNFalpha inhibitors or antagonists
AR053114A1 (es) 2005-01-12 2007-04-25 Aventis Pharma Inc Sal monopotasica del acido 2-{[2-(-2-metilamino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(fenilpiridin-2-il-amino)-propionico,inhibidora de ikk-2 quinasa
WO2006076681A2 (en) 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
CN101103028A (zh) 2005-01-14 2008-01-09 神经能质公司 经杂芳基取代的喹啉-4-基氨类似物
US20060264897A1 (en) 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2006081388A2 (en) 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
US20060221197A1 (en) 2005-03-30 2006-10-05 Jung Edward K Image transformation estimator of an imaging device
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US8476319B2 (en) 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
MX2007011105A (es) 2005-03-10 2007-10-08 Pfizer Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
CA2601468A1 (en) 2005-03-14 2006-09-21 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EP1861359B1 (en) 2005-03-17 2012-11-14 Pfizer Inc. N-(n-sulfonylaminomethyl)cyclopropanecarboxamide derivatives useful for the treatment of pain
EP1863453A2 (en) 2005-03-29 2007-12-12 Evonik Röhm GmbH Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
ES2382876T3 (es) 2005-05-31 2012-06-14 Pfizer, Inc. Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
WO2007012064A2 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
BRPI0616363A2 (pt) 2005-09-26 2011-06-14 Piedmont Pharmaceuticals Llc mÉtodos para tratamento e prevenÇço de otite mÉdia usando realÇadores de penetraÇço quÍmica para facilitar a liberaÇço de fÁrmaco transmembrana para dentro do ouvido mÉdio
US20080318918A1 (en) 2005-09-26 2008-12-25 Paulsen Neil E Methods for Treatment and Prevention of Otitis Media Using Nonionic Surfactants to Facilitate Transmembrane Drug Delivery into the Middle Ear
US20090246255A1 (en) * 2005-09-28 2009-10-01 Thomas Meyer Pharmaceutical Compositions for the Treatment of Inner Ear Disorders
CA2620248A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US20070110788A1 (en) 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP4273235B2 (ja) * 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン４阻害薬
AR061571A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
TW200819458A (en) 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20080103118A1 (en) 2006-10-27 2008-05-01 Iomedix Development International Srl Composition for improving blood cholesterol levels
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
EP2150244A1 (en) 2007-04-23 2010-02-10 House Ear Institute Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
KR20190026056A (ko) 2008-04-21 2019-03-12 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
BRPI0912482A2 (pt) 2008-05-14 2020-08-18 Otonomy, Inc composições de corticosteróide de liberação controlada e métodos para o tratamento de distúrbios auriculares
WO2009142719A2 (en) 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US20100016218A1 (en) 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
EP2306975A4 (en) 2008-07-21 2012-10-31 Otonomy Inc CONTROLLED RELEASE COMPOSITIONS MODULATING THE OTIC STRUCTURE AND MODULATING THE NATURAL IMMUNE SYSTEM AND METHODS OF TREATING OTIC DISORDERS
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
AU2009307825A1 (en) 2008-10-22 2010-04-29 Rick FRIEDMAN Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
JP5376987B2 (ja) 2009-02-18 2013-12-25 キヤノン株式会社 レチクルの製造方法、および面形状計測装置
JP6395687B2 (ja) * 2015-10-16 2018-09-26 株式会社カプコン 映像生成方法、映像生成プログラムおよび映像生成装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107791B1 (en) * 1998-09-04 2007-05-30 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2551359C1 (ru) * 2013-11-28 2015-05-20 Олег Ростиславович Михайлов Наноразмерная слабо закристаллизованная модификация 4-метил-n-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2751697C1 (ru) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Средство для лечения отитов наружного слухового прохода у собак

Also Published As

Publication number Publication date
US11123286B2 (en) 2021-09-21
KR20210107137A (ko) 2021-08-31
AU2009239429A1 (en) 2009-10-29
WO2009132050A3 (en) 2010-01-14
WO2009132050A2 (en) 2009-10-29
RU2010147298A (ru) 2012-05-27
JP2011518195A (ja) 2011-06-23
KR20200035508A (ko) 2020-04-03
WO2009132050A9 (en) 2011-02-03
IL251768A0 (en) 2017-06-29
KR20100135299A (ko) 2010-12-24
US20090306225A1 (en) 2009-12-10
US9132087B2 (en) 2015-09-15
IL251768B (en) 2022-02-01
JP2020147610A (ja) 2020-09-17
US20160095902A1 (en) 2016-04-07
US20220040096A1 (en) 2022-02-10
JP6147653B2 (ja) 2017-06-14
KR101449785B1 (ko) 2014-10-14
HK1209055A1 (en) 2016-03-24
CN102014957A (zh) 2011-04-13
US20200230051A1 (en) 2020-07-23
AU2009239429B2 (en) 2013-08-29
JP2019085423A (ja) 2019-06-06
US11123285B2 (en) 2021-09-21
US10751281B2 (en) 2020-08-25
BRPI0910850B1 (pt) 2022-06-14
MX2010011545A (es) 2011-04-11
US20160243028A1 (en) 2016-08-25
US20160228357A1 (en) 2016-08-11
KR20130097813A (ko) 2013-09-03
US20190307678A1 (en) 2019-10-10
IL208549A (en) 2017-04-30
US20240358634A1 (en) 2024-10-31
JP2016026218A (ja) 2016-02-12
BRPI0910850A2 (pt) 2020-08-25
KR20190026056A (ko) 2019-03-12
JP2014058557A (ja) 2014-04-03
KR102340754B1 (ko) 2021-12-16
CN102014957B (zh) 2014-12-10
EP2278999A4 (en) 2015-04-22
KR20160029870A (ko) 2016-03-15
CN104491864A (zh) 2015-04-08
IL208549A0 (en) 2010-12-30
JP6544535B2 (ja) 2019-07-17
CA2721927A1 (en) 2009-10-29
US10272034B2 (en) 2019-04-30
JP6296565B2 (ja) 2018-03-20
JP2017119723A (ja) 2017-07-06
EP2278999A2 (en) 2011-02-02
CA2721927C (en) 2014-01-28

Similar Documents

Publication Publication Date Title
RU2499592C2 (ru) Фармацевтическая композиция для лечения ушных заболеваний
JP2019524657A5 (ru)
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
JP6257326B2 (ja) 神経因性疼痛におけるマロノニトリルアミドの使用
HRP20140920T1 (hr) Farmaceutski pripravci za lijeäśenje poremeä†aja unutrašnjeg uha
CA2959404A1 (en) Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
CY1105202T1 (el) Διασπειρομενες φαρμακευτικες συνθεσεις
RU2010150863A (ru) Фармацевтическая композиция для лечения ушных заболеваний
ES2694775T3 (es) Composiciones que comprenden finafloxacina y métodos de tratamiento de infecciones oftálmicas, óticas y nasales
KR20100052556A (ko) 난청 치료 및 예방을 위한 1-아미노-알킬시클로헥산 유도체
EA201992162A1 (ru) Составы на основе нирапариба
JP2012506436A (ja) 代謝型グルタミン酸受容体の調節による内耳の疾病の処置および／または予防
WO2015031393A1 (en) Treatment of pediatric otic disorders
RU2014114499A (ru) Препараты {2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил}амида циклопропанкарбоновой кислоты
US11162071B2 (en) Compositions and methods for generating hair cells by upregulating JAG-1
US20200080055A1 (en) Compositions and methods for generating hair cells by upregulating pi3k
JP2010506937A (ja) スピロヘータ及びその他の偏性細胞内細菌性疾患の治療及び管理のために免疫調節化合物を用いる方法及び組成物
JP2012148995A (ja) 難聴疾患の予防又は治療剤
TW201141468A (en) Neramexane for the treatment or prevention of inner ear disorders
TW202103692A (zh) 用於治療聽力損失之組合物及方法
WO2020163812A1 (en) Valproic acid compounds and wnt agonists for treating ear disorders
JP2015515971A5 (ru)
Worsøe et al. Intratympanic steroid prevents long-term spiral ganglion neuron loss in experimental meningitis
JP2019524672A5 (ru)
WO2006012146A3 (en) Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200422